Cizzle Brands Lands Title Sponsorship for the CWENCH All Canadian Basketball Games

Cizzle Brands Lands Title Sponsorship for the CWENCH All Canadian Basketball Games

CWENCH Hydration™ has become the title sponsor of the CWENCH All Canadian Basketball Games, alongside other sponsors including Nike, TSN and Team Town. Cizzle Brands continues to build out its portfolio of sponsorships in Canadian grassroots sports, driving visibility for CWENCH Hydration™ as a healthy and great-tasting hydration option for athletes of all ages.

Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) ( the "Company" or "Cizzle Brands") , is pleased to announce that its flagship brand CWENCH Hydration™ is gaining further prominence in Canadian athletics through a five-year title sponsorship agreement of the CWENCH All Canadian Basketball Games, a three-day NBA-sanctioned event for Canadian male and female senior high school basketball players taking place on Friday, April 4, 2025 and Saturday, April 5, 2025. The event will be broadcast across Canada on TSN, and will have pre-promotion during the network's coverage of the NCAA® March Madness® tournaments this month.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320762204/en/

CWENCH Hydration is now title sponsor of the CWENCH All Canadian Games, a three-day event that celebrates Canada's top 24 senior male and female Canadian high school basketball players.

CWENCH Hydration is now title sponsor of the CWENCH All Canadian Games, a three-day event that celebrates Canada's top 24 senior male and female Canadian high school basketball players.

In addition to title sponsorship of the CWENCH All Canadian Basketball Games, the five-year agreement provides Cizzle Brands with comprehensive sponsorship rights for the promotion of its brands. This includes the naming rights for the event, naming rights for the CWENCH Player of the Game, the CWENCH logo appearing on all players' jerseys, commercial spots during the national broadcast on TSN, bench rights and exclusivity in the hydration category.

Also, as part the event, all of the athletes will take part in clinical sweat-testing trials to measure the impact that CWENCH Hydration™ has on performance.

Supporting grassroots sports initiatives in Canada is core to Cizzle Brands' ethos as a company, and has proven to be especially impactful for the early-stage growth of CWENCH Hydration™ in the North American marketplace. In addition to Cizzle Brands' recently announced sponsorship of the CWENCH All Canadian Volleyball Games, CWENCH also sponsors 500 youth hockey teams in Canada, representing over 12,000 youth hockey players. Last year, Cizzle Brands also obtained a sponsorship deal with Canlan Sports for a major four-rink hockey complex in the Toronto area, which is now named CWENCH Centre - A Canlan Sports Community . These efforts have contributed to driving strong demand for CWENCH Hydration™, with many of its leading retail and distribution partners re-ordering product at a fast pace, as further detailed in the Company's March 6, 2025 press release.

The CWENCH All Canadian Games will feature the top 24 senior male and female Canadian high school basketball players as selected by a committee including provincial and national representatives, clubs, coaches, scouts, and media from across the country. At the Athlete Institute in Orangeville, Ontario (near Toronto), participants engage in a series of activities over three days. These activities include on-and-off court training, practices and scrimmages in front of NBA personnel, a 3-Point Shootout, a Slam Dunk Competition, and Boys and Girls games. As an NBA-sanctioned event, the CWENCH All Canadian Basketball Games attract representation from the majority of the National Basketball Association's organizations.

More information about the CWENCH All Canadian Basketball Games can be found on the event's website: https://www.cwenchallcanadian.com .

Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, "We are delighted to sponsor the CWENCH All Canadian Basketball Games. The impact that this event has had on Canadians coast-to-coast is staggering. From a brand recognition standpoint, it will be instrumental to our continued growth and, as an organization, we take great pride in supporting grassroots athletics across Canada. The CWENCH All-Canadian Games will be a key catalyst for the continued growth of CWENCH Hydration™."

Jesse Tipping, CEO of the Athlete Institute Ltd., which is organizing games, added: "Cizzle Brands is an incredible Canadian company that puts the needs and health of young athletes at the forefront. I am proud to have CWENCH Hydration™ be the title sponsor for the games and look forward to our future together."

"As the Official Broadcaster of the CWENCH All Canadian Games, it's an honour for TSN to shine the spotlight on Canada's emerging young basketball players," said Shawn Redmond, VP, Bell Media Sports. "Canadian players are making a massive impact on the sport at all levels, and the CWENCH All Canadian Games are a key stepping stone, ensuring the next generation has a national platform to showcase their talents for fans."

About Cizzle Brands Corporation

Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 1,200 stores in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle.

For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com/

For more information about CWENCH Hydration™, please visit: https://www.cwenchhydration.com

For more information about the CWENCH All Canadian Games, please visit: https://www.cwenchallcanadian.com

Notice Regarding Images and Links: This press release may contain images and/or links to outside web pages, which could play an important role in providing the full context of the news update being conveyed through this press release. Some news aggregation services may remove these images and/or links at their discretion. Therefore, readers are encouraged to access SEDAR+ or the News section of the Cizzle Brands Corporation website to view this press release containing all images and/or links as originally published.

On behalf of the Board of Directors of the Company,

Cizzle Brands Corporation

"John Celenza"

John Celenza, Founder, Chairman, and Chief Executive Officer

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company.

Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.

Setti Coscarella
Head of Corporate Development
investors@cizzlebrands.com
1-844-588-2088

News Provided by Business Wire via QuoteMedia

CZZL:AQL
The Conversation (0)
Cizzle Brands Expands Availability of CWENCH Hydration at all Fortinos Locations in Ontario

Cizzle Brands Expands Availability of CWENCH Hydration at all Fortinos Locations in Ontario

Approximately two months after the chain-wide launch of CWENCH's hydration mix powder in Fortinos stores (February of 2025), CWENCH Hydration™ is now fully represented at Fortinos with the addition of its ready-to-drink Tetra Pak® format at all Fortinos locations, strengthening the footprint of CWENCH Hydration™ in key Ontario population centres where the Company is strategically commercializing its flagship product line.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration With Availability at United Supermarkets in Texas

Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration With Availability at United Supermarkets in Texas

The placement of CWENCH Hydration™ at United Supermarkets, a well-known chain of supermarkets in central and northern Texas, is part of Cizzle Brands' plan to strategically add to its U.S. presence in 2025.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands Announces that All 134 Metro Locations in Ontario Will be Offering CWENCH Hydration Ready-to-Drink Beverages

Cizzle Brands Announces that All 134 Metro Locations in Ontario Will be Offering CWENCH Hydration Ready-to-Drink Beverages

The availability of CWENCH Hydration™ in its ready-to-drink format at all 134 Metro locations in Ontario follows only three months after the initial launch of CWENCH's Hydration Mix with Metro in its Ontario stores.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands' CWENCH Hydration Becomes USA Hockey's Official Hydration Partner

Cizzle Brands' CWENCH Hydration Becomes USA Hockey's Official Hydration Partner

As a proud supporter of grassroots hockey across North America, Cizzle Brands is embracing this opportunity to further enhance its U.S. presence with brand visibility throughout the entire USA Hockey network by virtue of this multi-year sponsorship.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cizzle Brands Adds to its Presence in Ontario with Placements of CWENCH Hydration in Healthy Planet and Farm Boy

Cizzle Brands Adds to its Presence in Ontario with Placements of CWENCH Hydration in Healthy Planet and Farm Boy

The availability of CWENCH Hydration™ in Healthy Planet and Farm Boy, both of which are leading retailers in Ontario, will further enhance visibility and availability of the product as its market share continues to increase.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.

ETFs are a popular choice as they allow investors to enter the market more safely compared to investing in standalone stocks. A key advantage is that even if one company in the ETF takes a hit, the impact will be less direct.

Below the Investing News Network takes a look at five small-cap biotech ETFs. The funds were selected using ETFdb.com, and their total assets under management (AUM) were under US$100 million as of May 20, 2025.

Keep reading...Show less
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX "Radiopharm"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the signing of a supply agreement that will provide Radiopharm with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177 Lu), to enable its usage in the clinical and potential future commercial development of the 177 Lu-based molecules in Radiopharm's development pipeline.

Under the terms of the agreement, Radiopharm will use ITM's n.c.a. 177 Lu across its clinical pipeline, including in key programs such as RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 (HER2-targeting nanobody, Phase 1), and RV01 (B7-H3-targeting monoclonal antibody, preclinical), for the treatment of solid tumors. Coupled with the targeting molecules that are designed to deliver ITM's n.c.a. 177 Lu directly to tumor sites, the radioisotope emits therapeutic beta radiation with the aim to destroy malignant cells in a highly precise and localized manner.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday May 21, 2025. Kave Niksefat senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee

DSMC concluded that Phase 1 study may continue as planned without any modifications

On track to complete the enrollment of the first two cohorts by mid-2025

Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, announced today that it has achieved a key milestone in its ongoing clinical development program for its clinical-stage radiotherapeutic asset, 177Lu-RAD204, as the Data and Safety Monitoring Committee (DSMC) has approved to proceed to the next dose in its Phase 1 clinical trial in patients with PD-L1 positive advanced cancers 1 . The DSMC is an independent multidisciplinary group that conducts detailed reviews of unblinded study data, discusses potential safety concerns and provides recommendations regarding trial continuation.

"We greatly appreciate the DSMC's judicious review of our first cohort of patients in the Phase 1 study of 177Lu-RAD204, which allows us to advance to the higher dose cohort in a variety of PD-L1- driven cancers," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "With this clearance from the DSMC, the increased number of active centers and expansion to multiple tumor types beyond Non-Small Cell Lung Cancer (NSCLC), we expect to accelerate our timelines for complete enrolment of the next cohort by mid-2025. We believe that RAD204 has the potential to strongly improve clinical outcomes for patients with PD-L1 positive advanced cancers and we look forward to seeing data from the first two cohorts of patients later this year."

The DSMC reviewed the first cohort of four patients treated with 30mCi of 177Lu-RAD204 and confirmed that there was positive safety, pharmacokinetic and biodistribution data and agreed that the study may continue without modifications. The second cohort of patients will start at 60mCi of Lu177 rather than 40mCi previously assumed in the protocol. The second cohort of patients is expected to be enrolled by mid-year 2025 and will include expansion to multiple tumor types including NSCLC, Small-Cell Lung Cancer (SCLC), Triple-negative Breast Cancer (TNBC), Cutaneous Melanoma, head and neck squamous cell carcinoma (HNSCC) and Endometrial Cancer.

There are currently four clinical trial sites actively screening and recruiting patients in Australia.

About 177Lu-RAD204:

RAD204 is a single-domain monoclonal antibody (sdAb) that targets PD-L1, a protein that helps control the immune system and is overexpressed in many solid cancers, making it an attractive therapeutic target in multiple tumor types, including NSCLC, SCLC, TNBC, Cutaneous Melanoma, HNSCC, and Endometrial Cancer. Previously published Phase I imaging data of 16 NSCLC patients with 99Tc-RAD204 demonstrated that the diagnostic compound is safe and is associated with acceptable dosimetry 2 .

Tumor targeting with radioimmunotherapies such as 177Lu-RAD204 has the potential to address resistance mechanisms to current standard-of-care treatment options.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com .

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com

Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×